![]() | Up a level |
Wilding, John ORCID: 0000-0003-2839-8404, Fernando, Kevin, Milne, Nicola, Evans, Marc, Ali, Amar, Bain, Steve, Hicks, Debbie, James, June, Newland-Jones, Philip, Patel, Dipesh et al (show 1 more authors)
(2018)
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice.
DIABETES THERAPY, 9 (5).
1757 - 1773.
Ali, Amar, Bain, Steve, Hicks, Debbie, Jones, Phillip Newland, Patel, Dipesh C, Evans, Marc, Fernando, Kevin, James, June, Milne, Nicola, Viljoen, Adie et al (show 2 more authors)
(2019)
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice.
DIABETES THERAPY, 10 (5).
1595 - 1622.
Wheeler, David C, James, June, Patel, Dipesh, Viljoen, Adie, Ali, Amar, Evans, Marc, Fernando, Kevin, Hicks, Debbie, Milne, Nicola, Newland-Jones, Philip et al (show 2 more authors)
(2020)
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes.
Diabetes therapy : research, treatment and education of diabetes and related disorders, 11 (12).
2757 - 2774.